Mostrar el registro sencillo del ítem

dc.contributor.authorKalempa Demeu, Lara Maria
dc.contributor.authorJahn Soares, Rodrigo
dc.contributor.authorSevero Miranda, Juliana
dc.contributor.authorPacheco-Lugo, Lisandro A.
dc.contributor.authorGonçalves Oliveira, Kelin
dc.contributor.authorCortez Plaza, Cristian Andrés
dc.contributor.authorBilliald, Philippe
dc.contributor.authorFerreira de Moura, Juliana
dc.contributor.authorYoshida, Nobuko
dc.contributor.authorMagalhães Alvarenga, Larissa
dc.contributor.authorDuarte DaRocha, Wanderson
dc.description.abstractTrypanosoma cruzi is a flagellate protozoan pathogen that causes Chagas disease. Currently there is no preventive treatment and the efficiency of the two drugs available is limited to the acute phase. Therefore, there is an unmet need for innovative tools to block transmission in endemic areas. In this study, we engineered a novel recombinant molecule able to adhere to the T. cruzi surface, termed scFv-10D8, that consists of a single-chain variable fragment (scFv) derived from mAb-10D8 that targets gp35/50. The synthetic gene encoding scFv-10D8 was cloned and fused to a 6×His tag and expressed in a prokaryotic expression system. Total periplasmic or 6xHis tag affinity-purified fractions of scFv-10D8 retained the capacity to bind to gp35/50, as shown by Western blot analyses. Pre-incubation of metacyclic trypomastigotes with scFv-10D8 showed a remarkable reduction in cell invasion capacity. Our results suggest that scFv-10D8 can be used in a paratransgenic approach to target parasites in insect vectors, avoiding dissemination of infective forms. Such advances in the development of this functional molecule will surely prompt the improvement of alternative strategies to control Chagas disease by targeting mammalian host stages.eng
dc.publisherJavier Marcelo Di Noia, Institut de recherches cliniques de Montreal, CANADAeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.sourcePLoS ONEeng
dc.source14(10), (2019)spa
dc.source.uri pone.0223773eng
dc.subjectTrypanosoma cruzieng
dc.subjectParasitic diseaseseng
dc.subjectChagas diseaseeng
dc.subjectProtein extractioneng
dc.subjectProtozoan infectionseng
dc.subjectSequence databaseseng
dc.titleEngineering a single-chain antibody against Trypanosoma cruzi metacyclic trypomastigotes to block cell invasioneng
dc.source.bibliographicCitationTibayrenc M, Barnabe´ C, Telleria J. Reticulate Evolution in: Medical and Epidemiological Implications In: Telleria J, Tibayrenc M, editors. American trypanosomiasis: Chagas disease One hundred years of research. Burlington: Elsevier; 2010. 475–488.eng
dc.source.bibliographicCitationWorld Health Organization Health Topics, Chagas disease, 2017. en/. Accessed 04 Oct 2017eng
dc.source.bibliographicCitationSilveira AC, Dias JCP. O controle da transmissão vetorial. Rev Soc Bras Med Trop 44 Supplement. 2011; 2:52–63.
dc.source.bibliographicCitationCoura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions: a comprehensive review. Mem Inst Oswaldo Cruz. 2015; 110:277–282. 0074-0276140362 PMID: 25466622eng
dc.source.bibliographicCitationBrowne AJ, Guerra CA, Alves RV, da Costa VM, Wilson AL, Pigott DM, et al. The contemporary distribution of Trypanosoma cruzi infection in humans, alternative hosts and vectors. Sci Data. 2017; 4:170050. PMID: 28398292eng
dc.source.bibliographicCitationWorld Health Organization (2015) Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec Feb 90:33–43eng
dc.source.bibliographicCitationGurgel-Gonc¸alves R, Galvão C, Costa J, Peterson AT. Geographic distribution of Chagas disease vectors in brazil based on ecological niche modeling. J Trop Med. 2012;:Article ID 705326. 10.1155/2012/705326 PMID: 22523500eng
dc.source.bibliographicCitationVinhaes MC, de Oliveira SV, Reis PO, de Lacerda Sousa AC, Silva RA, Obara MT,et al. Assessing the vulnerability of Brazilian municipalities to the vectorial transmission of Trypanosoma cruzi using multicriteria decision analysis. Acta Trop. 2014; 137:105–110. 007 PMID: 24857942eng
dc.source.bibliographicCitationMinistério da Saúde (BR) Secretaria de vigilância em saúde. Guía de vigilância em saúde. Ministério da Saúde, Brasília, 2007por
dc.source.bibliographicCitation(2016) Brazilian consensus on Chagas disease. Epidemiol Serv Saúde, Brasília 25(nu´m. esp.):7–86eng
dc.source.bibliographicCitationMougabure-Cueto G, Picollo MI. Insecticide resistance in vector Chagas disease: evolution, mechanisms and management. Acta Trop 2015; 149:70–85. 014 PMID: 26003952eng
dc.source.bibliographicCitationUrbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003; 19:495–501. PMID: 14580960eng
dc.source.bibliographicCitationFilardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987; 81:755–759. 0035-9203(87)90020-4 PMID: 3130683eng
dc.source.bibliographicCitationTeston AP, Monteiro WM, Reis D, Bossolani GD, Gomes ML, De Araújo SM, et al. In vivo susceptibility to Benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop Med Int Health. 2013; 18:85–95. PMID: 23130989eng
dc.source.bibliographicCitationBaral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. 2016; 12:580–584. PMID: 16604085eng
dc.source.bibliographicCitationArias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernández-Quero J, Magez S, et al. Nanobody conjugated PLGA nanoparticles for active targeting of African trypanosomiasis. J Control Release. 2014; 197 10:190–198. PMID: 25445702eng
dc.source.bibliographicCitationUnciti-Broceta JD, Arias JL, Maceira J, Soriano M, Ortiz-González M, Hernández-Quero J, et al. Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis. PLoS Pathog. 2015; 25:e1004942(6). PMID: 26110623eng
dc.source.bibliographicCitationStijlemans B, Caljon G, Natesan SK, Saerens D, Conrath K, Pérez-Morga D, et al. High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog. 2011; 7:e1002072. PMID: 21698216eng
dc.source.bibliographicCitationBerasategui A, Shukla S, Salem H, Kaltenpoth M. Potential applications of insect symbionts in biotechnology. Appl Microbiol Biotechnol. 2016; 100:1567–1577. PMID: 26659224eng
dc.source.bibliographicCitationHurwitz I, Fieck A, Read A, Hillesland H, Klein N, Kang A, et al. Paratransgenic control of vector borne diseases. Int J Biol Sci. 2011; 7:1334–1344. PMID: 22110385eng
dc.source.bibliographicCitationDurvasula RV, Sundaram RK, Kirsch P, Hurwitz I, Crawford CV, Dotson E, et al. Genetic transformation of a Corynebacterial symbiont from the Chagas disease vector Triatoma infestans. Exp Parasitol. 2018; 119:94–98. PMID: 18331732eng
dc.source.bibliographicCitationMatthews S, Rao VS, Durvasula RV. Modeling horizontal gene transfer (HGT) in the gut of the Chagas disease vector Rhodnius prolixus. Parasites Vectors. 2011; 4:77. 77 PMID: 21569540eng
dc.source.bibliographicCitationDe Vooght CG, De Ridder K, Van Den Abbeele J. Delivery of a functional anti-trypanosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidius. Microb Cell Factories. 2014; 13:156. PMID: 25376234eng
dc.source.bibliographicCitationYoshida N, Mortara RA, Araguth MF, Gonzalez JC, Russo M. Metacyclic neutralizing effect of monoclonal antibody 10D8 directed to the 35- and 50-kilodalton surface glycoconjugates of Trypanosoma cruzi. Infect Immun. 1989; 57:1663–1667 PMID: 2656520eng
dc.source.bibliographicCitationMortara RA, Da Silva S, Araguth MF, Blanco SA, Yoshida N. Polymorphism of the 35- and 50-kilodalton surface glycoconjugates of Trypanosoma cruzi metacyclic trypomastigotes. Infect Immun. 1992; 60:4673–4678 PMID: 1328061eng
dc.source.bibliographicCitationUrban I, Santurio LB, Chidichimo A, Yu H, Chen X, Mucci J, et l. Molecular diversity of the Trypanosoma cruzi TcSMUG family of mucin genes and proteins. Biochem J. 2011; 438:303–313. 1042/BJ20110683 PMID: 21651499eng
dc.source.bibliographicCitationYoshida N. Molecular basis of mammalian cell invasion by Trypanosoma cruzi. An Acad Bras Cienc. 2006; 78:87–111. PMID: 16532210eng
dc.source.bibliographicCitationJones C, Todeschini AR, Agrellos OA, Previato JO, Mendonc¸a-Previato L. Heterogeneity in the biosynthesis of mucin O-glycans from Trypanosoma cruzi tulahuen strain with the expression of novel galactofuranosyl- containing oligosaccharides. Biochemistry. 2004/ 43(37):11889–97. bi048942u PMID: 15362875eng
dc.source.bibliographicCitationMilenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991; 51:6363–71 PMID: 1933899eng
dc.source.bibliographicCitationKuan CT, Srivastava N, Mclendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant singlechain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer. 2010; 127:598–611. 25062 PMID: 19937796eng
dc.source.bibliographicCitationCrivianu-Gaita V, ThompsonM (2016) Aptamers, antibody scFv, and antibody Fab’ fragments: an overview and comparison of three of the most versatile biosensor biorecognition elements. Biosens Bioelectron. 2016; 85:32–45. PMID: 27155114eng
dc.source.bibliographicCitationFields C, O’Connell D, Xiao S, Lee GU, Billiald P, Muzard J. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nat Protoc. 2013; 8:1125–1148. PMID: 23680984eng
dc.source.bibliographicCitationLyskov S, Chou FC, Conchúir SO´ , Der BS, Drew K, Kuroda D, et al. Serverification of molecular modeling applications: the Rosetta online server that includes everyone (ROSIE). PLoS One. 2013 8: e63906. PMID: 23717507eng
dc.source.bibliographicCitationGhoorah AW, Devignes MD, Smaïl-Tabbone M, Ritchie DW. Protein docking using case-based reasoning. Proteins. 2013; 81:2150–2158. PMID: 24123156eng
dc.source.bibliographicCitationMcguffin LJ, Atkins JD, Salehe BR, Shuid AN, Roche DB. IntFOLD: an integrated server for modelling protein structures and functions from amino acid sequences. Nucleic Acids Res. 2015; 43:W169– W173. PMID: 25820431eng
dc.source.bibliographicCitationKarim-Silva S, Moura Jd, Noiray M, Minozzo JC, Aubrey N, Alvarenga LM, et al. Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism. Immunol Lett. 2016; 176:90–6. PMID: 27288291eng
dc.source.bibliographicCitationZingales B, Andrade SG, Briones MRS, Campbell DA, Chiari E, Fernandes O, et al. A new consensus for Typanosoma cruzi intraespecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009; 104:1051–1054. PMID: 20027478eng
dc.source.bibliographicCitationContreras VT, Araujo-Jorge TC, Bonaldo MC, Thomaz N, Barbosa HS, Meirelles N, et al. Biological aspect of the Dm28c clone of Trypanosoma cruzi after metacyclogenesis in chemically defined media. Mem Inst Oswaldo Cruz. 1988; 83:123–133. PMID: 3074237eng
dc.source.bibliographicCitationTeixeira MMG, Yoshida N. Stage-specific surface antigens of metacyclic trypomastigotes of Trypanosoma cruzi identified by monoclonal antibodies. Mol Biochem Parasitol. 1986; 18:271–282. https://doi. org/10.1016/0166-6851(86)90085-x PMID: 3515178eng
dc.source.bibliographicCitationSerrano AA, Schenkman S, Yoshida N, Mehlert A, Richardson JM, Ferguson MA. The lipid structure of the glycosylphosphatidylinositol-anchored mucin-like sialic acid acceptors of Trypanosoma cruzi changes during parasite differentiation from epimastigotes to infective metacyclic trypomastigote forms. J Biol Chem. 1995; 270:27244–27253. PMID: 7592983eng
dc.source.bibliographicCitationMcgwire BS, Olson CL, Tack BF, Engman DM. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis. 2003; 188:146–152. PMID: 12825184eng
dc.source.bibliographicCitationSmulski C, Labovsky V, Levy G, Hontebeyrie M, Hoebeke J, Levin MJ. Structural basis of the crossreaction between an antibody to the Trypanosoma cruzi ribosomal P2β protein and the human β1 adrenergic receptor. FASEB J. 2006; 20:1396–1406. PMID: 16816115eng
dc.source.bibliographicCitationAyub MJ, Nyambega B, Simonetti L, Duffy T, Longhi SA, Gómez KA, et al. Selective blockade of trypanosomatid protein synthesis by a recombinant antibody anti-Trypanosoma cruzi P2β protein. PLOS ONE. 2012: 7:e36233. PMID: 22570698eng
dc.source.bibliographicCitationMendonc¸a-Previato L, Penha L, Garcez TC, Jones C, Previato JO. Addition of alpha-O-GlcNAc to threonine residues define the post-translational modification of mucin-like molecules in Trypanosoma cruzi. Glycoconj J. 2013; 30:659–666. PMID: 23430107eng
dc.source.bibliographicCitationOssysek K, Uchański T, Kulesza M, Bzowska M, Klaus T, Woś K, et al. A New expression vector facilitating production and functional analysis of scFv antibody fragments selected from Tomlinson I+J phagemid libraries. Immunol Lett. 2015; 167:95–102. PMID: 26219832eng
dc.source.bibliographicCitationLim KP, Li H, Nathan S. Expression and purification of a recombinant scFv towards the exotoxin of the pathogen, Burkholderia pseudomallei. J Microbiol. 2004; 42:126–132 PMID: 15357306eng
dc.source.bibliographicCitationYusakul G, Sakamoto S, Nuntawong P, Tanaka H, Morimoto S. Different expression systems resulted in varied binding properties of anti–paclitaxel single–chain variable fragment antibody clone 1C2. J Nat Med. 2018; 72:310–316. PMID: 29027080eng
dc.source.bibliographicCitationYoshida N, Dorta ML, Ferreira AT, Oshiro ME, Mortara RA, Acosta-Serrano A, et l. Removal of sialic acid from mucin-like surface molecules of Trypanosoma cruzi metacyclic trypomastigotes enhances parasite-host cell interaction. Mol Biochem Parasitol. 1997; 84:57–67. 6851(96)02783-1 PMID: 9041521eng
dc.source.bibliographicCitationLebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development. N Biotechnol. 2018; 44:31–40. 2018.04.006 PMID: 29689305eng
dc.source.bibliographicCitationCámara MLM, Balouz V, Centeno Cameán C, Cori CR, Kashiwagi GA, Gil SA, et al. Trypanosoma cruzi surface mucins are involved in the attachment to the Triatoma infestans rectal ampoule. PLoS Negl Trop Dis. 2019; 13(5):e0007418. PMID: 31107901eng

Ficheros en el ítem


Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos
    Artículos científicos evaluados por pares

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional